Meta-analysis of rosuvastatin efficacy in prevention of contrast-induced acute kidney injury

Jing Zhang¹
Ying Guo¹
Qi Jin¹
Li Bian²
Ping Lin³

¹Department of Nephrology, China-Japan Union Hospital of Jilin University, Changchun, People’s Republic of China; ²Department of Radiotherapy, The Second Hospital of Jilin University, Changchun, People’s Republic of China; ³Department of Nephrology, The First Hospital of Jilin University, Changchun, People’s Republic of China

Background: Contrast-induced nephropathy (CIN) is a complication after the intravascular administration of a contrast medium injection. Previous studies have investigated statins as therapy for CIN due to its positive results in the prevention of contrast-induced acute kidney injury (CI-AKI). Nevertheless, the beneficial effects of rosuvastatin pretreatment in preventing CIN in patients with acute coronary syndromes still remain controversial. In this study, we performed a meta-analysis of randomized controlled trials (RCTs) to evaluate the beneficial impact of rosuvastatin in the prevention of CI-AKI in acute coronary syndrome patients.

Methods: PubMed, Embase, and Cochrane library were searched, for RCTs, updated on January 2018. The method was to evaluate rosuvastatin prior to angiography for the prevention of CI-AKI in patients undergoing coronary angiography, of which the main outcome was the incidence of CIN.

Results: A total of five RCTs were included in this analysis. Patients treated with rosuvastatin prior to invasive angiography had a significantly lower incidence of CI-AKI than controls (odds ratio [OR]: 0.53, 95% CI: 0.40–0.71, \(P<0.0001\)). Moreover, the subgroup analysis also showed that the benefit of rosuvastatin for patients with chronic kidney disease (OR: 0.49, 95% CI: 0.26–0.92, \(P=0.03\)) and diabetes mellitus (OR: 0.56, 95% CI: 0.38–0.83, \(P=0.004\)) which was consistent in compared with the respective control groups.

Conclusion: The findings of this meta-analysis suggest that the preoperative rosuvastatin treatment significantly reduces the risk of renal insufficiency of CIN in at-risk patients with chronic kidney disease or diabetes mellitus. Additional studies are needed to identify at-risk patients, provide optimum dose peri-procedural treatment, and reduce the incidence of CIN.

Keywords: contrast-induced nephropathy, coronary angiography, rosuvastatin, meta-analysis

Introduction

Contrast-induced nephropathy (CIN) is characterized by acute impairment of renal function after contrast exposure.¹ Patients with acute coronary syndrome (ACS) undergoing primary percutaneous intervention (p-PCI) are at a higher risk of developing contrast-induced acute kidney injury (CI-AKI).² Moreover, the incidence of contrast nephropathy was associated with patient characteristics that are risk factors for this disease.³,⁴ As CI-AKI is associated with increased short- and long-term morbidity and mortality, nonfatal cardiovascular events, and a longer hospital stay,³ the adoption of optimal therapeutic strategies is needed to prevent CIN, offering an opportunity to reduce patient morbidity and mortality.

In clinical practice, a number of studies have shown that the pleiotropic properties of statins exert a beneficial impact in the prevention of contrast nephropathy.⁶ Apart from their cholesterol-lowering effects, statins have anti-inflammatory, antithrombotic, and antioxidative properties and may exercise nephron-protective action, thereby improving...
the endothelial function and reducing vascular inflammation and oxidative stress. These favorable activities have a direct preventive effect against the development of CI-AKI. However, the results concerning the efficacy of statin therapy in the prevention of CI-AKI are inconsistent. The hydrophilic form of the statin rosuvastatin may have better potential for prevention of CIN than other statin forms, probably owing to its longer plasma half-life and stronger anti-inflammatory effect. Previous randomized controlled trials (RCTs) focused mainly on the application of the lipophilic form of rosuvastatin for the prevention of CIN, but conflicting results have been reported.

Therefore, in this study, we performed a meta-analysis of RCTs to evaluate the efficacy of rosuvastatin pretreatment for the prevention of CIN as compared with placebo treatment.

Methods

Search strategy
To find all related articles, two investigators independently searched electronic databases (PubMed, Embase, and Cochrane Library) up to January 2018. The keywords “rosuvastatin” and “contrast-induced acute kidney injury,” as well as relevant Medical Subject Heading terms were used in the search. We also checked the reference lists of all articles for additional eligible studies.

Eligibility criteria
To be included in the meta-analysis, the studies had to meet the following criteria: 1) RCTs comparing rosuvastatin pretreatment with placebo treatment in patients undergoing PCI; 2) they provided information about CI-AKI; 3) the outcome of interest was the incidence of CIN; 4) each paper had to be written in English.

Quality assessment
Two investigators independently rated the quality of the eligible RCTs. We choose the risk of bias items for RCTs recommended by The Cochrane Handbook for Systematic Reviews of Interventions.

Data extraction
Two authors independently extracted the relevant data from each article. Any disagreement was resolved by consensus. The data extracted from the eligible studies included the following information: name of the first author, year of publication, characteristics of the trials, number of study patients, mean age, mean baseline SCr, and definition of CIN in each trial.

Statistical analysis
All outcome comparisons were conducted and estimates calculated using the Review Manager version 5.3 software (Revman; The Cochrane Collaboration, Oxford, UK). Odds ratios (ORs) and their 95% CIs were calculated to assess the CIN events and make comparisons between the rosuvastatin and the control groups. The ORs and their 95% CIs were also mentioned in the summary statistics in the pooled subgroup analysis for patients with chronic kidney disease (CKD) or diabetes mellitus (DM).

A sensitivity analysis was also performed to examine the overall impact of heterogeneity on meta-analysis results. The I² test was employed to evaluate the heterogeneity of the results. An I²-value ≥50% was considered to indicate moderate and high heterogeneity, whereas an I²-value <50% showed low heterogeneity. A P-value <0.05 was considered statistically significant.

Results

Overview of literature search and study characteristics
A total of 213 studies were identified and reviewed according to the criteria described in the methods, of which 10 publications were evaluated in more detail, but some did not provide information on the endpoint outcomes.

Thus, a total of five RCTs were finally included in the present analysis. The search process is illustrated in Figure 1. All included studies in this meta-analysis were considered to be at least of moderate quality. Detailed information on the medication protocols of the eligible studies is presented in Table 1.

Effect of rosuvastatin on the incidence of CI-AKI
The data pooled from all five articles included in our research showed that the risk of CI-AKI (OR: 0.53, 95% CI: 0.40–0.71, P<0.0001) in the atorvastatin treatment group was lower than that in the control group (Figure 2).

Subgroup analysis of the effect of rosuvastatin on the incidence of CI-AKI
Rosuvastatin reduced also the risk of CI-AKI in patients with CKD (OR: 0.45, 95% CI: 0.21–0.95, P=0.04) (Figure 3) and DM (OR: 0.56, 95% CI: 0.38–0.83, P=0.004) (Figure 4), as compared with that in the placebo group.
Discussion

The pathophysiological mechanism of CIN is still not entirely clear. Multiple mechanisms may be involved; in particular, adenosine, angiotensin, vasopressin, and endothelin secretion after contrast exposure is a logical cause for the reduction in the synthesis of nitric oxide and the induction of oxidative stress, causing hypoxia in the renal medulla. More recently, other renal damage mechanisms have been associated with the development of cellular lesions, necrosis, interstitial inflammation, and tubular injury. It is noteworthy that the elevated preprocedural concentration of the high-sensitivity CRP was found to increase the risk of CIN in patients who had undergone PCI.

In addition to their lipid-lowering activities, statins are also known to downregulate the angiotensin receptor, limit the production of endothelial nitric oxide synthase, and have antithrombotic and anti-inflammatory properties, which altogether constitutes their pleiotropic effects. Due to these multidirectional activities, statins are considered to exert also a renoprotective effect and that the pretreatment with statin can affect the progression of the CI-AKI pathogenesis.

Basing on the beneficial clinical results observed in various subgroups of patients, we analyzed the additional functions of rosuvastatin which showed acute pleiotropic effects. In one of the studies included in our research, healthy patients without hyperlipidemia (low-density lipoprotein cholesterol levels: <130 mg/dL) but with elevated high-sensitivity CRP levels (>2.0 mg/L) and patients with estimated eGFR <60 mL/min/1.73 m² were found to be at the highest risk of CI-AKI. Furthermore, the short-term treatment with rosuvastatin was indicated to play a protective role by improving eGFR independently of the lipid fraction changes.
Table 1: Detailed medication protocols of the eligible studies

<table>
<thead>
<tr>
<th>Study</th>
<th>Patients number</th>
<th>Inclusion criteria</th>
<th>Protocol</th>
<th>Definition of CIN</th>
<th>Mean age, years</th>
<th>Mean baseline SCR, µmol/L or mg/dL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fahmy et al</td>
<td>100/100</td>
<td>Patients undergoing CAG</td>
<td>Rosuvastatin 20 mg/d from 3 days before to 7 days after procedure vs placebo</td>
<td>≥25% SCR or ≥44.2 µmol/L SCR within 48 hours</td>
<td>54.8±11.0/52.1±10.7</td>
<td>0.81±0.2/0.81±0.3 mg/dL</td>
</tr>
<tr>
<td>(2013)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leoncini et al</td>
<td>252/252</td>
<td>NSTE-ACS patients undergoing CAG with or without PCI</td>
<td>Rosuvastatin 40 mg followed by 20 mg/d vs placebo</td>
<td>≥25% SCR or ≥44.2 µmol/L SCR within 72 hours</td>
<td>66.2±12.4/66.1±13.5</td>
<td>0.95±0.27/0.96±0.28 mg/dL</td>
</tr>
<tr>
<td>(2014)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abaci et al</td>
<td>110/110</td>
<td>Patients undergoing CAG</td>
<td>Rosuvastatin 40 mg within 24 hours before and 20 mg/d for 2 days vs placebo</td>
<td>≥25% SCR or ≥44.2 µmol/L SCR 48–72 hours</td>
<td>67.5±8.9/67.7±8.9</td>
<td>1.3±0.4/1.4±0.5 mg/dL</td>
</tr>
<tr>
<td>(2015)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Msd et al</td>
<td>67/68</td>
<td>ACS patients undergoing PCI</td>
<td>Rosuvastatin 40 mg 2–6 hours before procedure vs placebo</td>
<td>≥25% SCR or ≥44.2 µmol/L SCR 24 hours</td>
<td>59.4±8.6/62.2±9.8</td>
<td>0.89±0.24/0.98±0.21 mg/dL</td>
</tr>
<tr>
<td>(2012)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Han et al</td>
<td>1,498/1,500</td>
<td>Patients with DM and CKD undergoing coronary/peripheral arterial diagnostic angiography, left ventriculography, or PCI were eligible</td>
<td>Rosuvastatin, 10 mg every evening, from 2 days before to 3 days after contrast medium administration (total dose of 50 mg of rosuvastatin over 5 days) or to a control group</td>
<td>≥25% SCR or ≥44.2 µmol/L SCR within 72 hours</td>
<td>61.45±8.64/61.44±8.64</td>
<td>95.08±22.92/94.95±20.84 mg/dL</td>
</tr>
<tr>
<td>(2014)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: CAG, coronary angiography; CIN, contrast-induced nephropathy; CKD, chronic kidney disease; DM, diabetes mellitus; PCI, percutaneous coronary intervention.
Meta-analysis of rosuvastatin efficacy in prevention of CI-AKI

**Figure 2**

Effect of rosuvastatin on the incidence of CI-AKI.

Abbreviations: CI-AKI, contrast-induced acute kidney injury; OR, odds ratio.

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Experimental Events Total</th>
<th>Control Events Total</th>
<th>Weight (%)</th>
<th>Odds ratio M–H, fixed, 95% CI</th>
<th>Odds ratio M–H, fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ahmed Eltahawy 2013</td>
<td>15</td>
<td>100</td>
<td>38</td>
<td>25.3</td>
<td>0.29 (0.15, 0.57)</td>
</tr>
<tr>
<td>Mario Leoncini 2014</td>
<td>17</td>
<td>252</td>
<td>38</td>
<td>27.8</td>
<td>0.41 (0.22, 0.74)</td>
</tr>
<tr>
<td>Okay Abaci 2015</td>
<td>6</td>
<td>103</td>
<td>9</td>
<td>6.6</td>
<td>0.66 (0.23, 1.93)</td>
</tr>
<tr>
<td>Oliveira 2012</td>
<td>6</td>
<td>67</td>
<td>5</td>
<td>3.5</td>
<td>1.24 (0.36, 4.27)</td>
</tr>
<tr>
<td>Yaling Han 2014</td>
<td>34</td>
<td>1,498</td>
<td>48</td>
<td>36.8</td>
<td>0.70 (0.45, 1.10)</td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td></td>
<td>2,020</td>
<td>2,025</td>
<td>100</td>
<td>0.53 (0.40, 0.71)</td>
</tr>
<tr>
<td><strong>Total events</strong></td>
<td>78</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Heterogeneity:</strong></td>
<td>$\chi^2=7.32$, $df=4$ ($P=0.12$); $I^2=45%$</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Test for overall effect:</strong></td>
<td>$Z=4.25$ ($P&lt;0.0001$)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Figure 3**

Influence of rosuvastatin treatment on the incidence of CI-AKI in patients with CKD.

Abbreviations: CI-AKI, contrast-induced acute kidney injury; CKD, chronic kidney disease; OR, odds ratio.

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Experimental Events Total</th>
<th>Control Events Total</th>
<th>Weight (%)</th>
<th>Odds ratio M–H, fixed, 95% CI</th>
<th>Odds ratio M–H, fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mario Leoncini 2014</td>
<td>9</td>
<td>105</td>
<td>22</td>
<td>69.6</td>
<td>0.35 (0.15, 0.81)</td>
</tr>
<tr>
<td>Okay Abaci 2015</td>
<td>6</td>
<td>103</td>
<td>9</td>
<td>29.1</td>
<td>0.66 (0.23, 1.93)</td>
</tr>
<tr>
<td>Oliveira 2012</td>
<td>1</td>
<td>8</td>
<td>0</td>
<td>1.3</td>
<td>4.20 (0.15, 117.92)</td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td></td>
<td>216</td>
<td>220</td>
<td>100</td>
<td>0.49 (0.26, 0.92)</td>
</tr>
<tr>
<td><strong>Total events</strong></td>
<td>16</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Heterogeneity:</strong></td>
<td>$\chi^2=2.49$, $df=2$ ($P=0.29$); $I^2=20%$</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Test for overall effect:</strong></td>
<td>$Z=2.21$ ($P=0.03$)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Figure 4**

Impact of rosuvastatin administration on the incidence of CI-AKI in patients with DM.

Abbreviations: CI-AKI, contrast-induced acute kidney injury; DM, diabetes mellitus; OR, odds ratio.

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Experimental Events Total</th>
<th>Control Events Total</th>
<th>Weight (%)</th>
<th>Odds ratio M–H, fixed, 95% CI</th>
<th>Odds ratio M–H, fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mario Leoncini 2014</td>
<td>6</td>
<td>50</td>
<td>13</td>
<td>15.9</td>
<td>0.46 (0.16, 1.32)</td>
</tr>
<tr>
<td>Yaling Han 2014</td>
<td>34</td>
<td>1,498</td>
<td>58</td>
<td>84.1</td>
<td>0.58 (0.38, 0.89)</td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td></td>
<td>1,548</td>
<td>1,557</td>
<td>100</td>
<td>0.56 (0.38, 0.83)</td>
</tr>
<tr>
<td><strong>Total events</strong></td>
<td>40</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Heterogeneity:</strong></td>
<td>$\chi^2=0.15$, $df=1$ ($P=0.70$); $I^2=0%$</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Test for overall effect:</strong></td>
<td>$Z=2.87$ ($P=0.004$)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

of RCTs with different inclusion criteria with insignificant heterogeneity among the included studies. Second, patients might have had differential responses to treatment with different doses of rosuvastatin. Third, the entire meta-analysis is based upon 5 RCTs, of which only three related to CKD and two related to DM, which limits the ability to statistically analyze the effect of rosuvastatin on the incidence of interested outcomes, so future research should be conducted to identify these subgroups.

Contrast administration is well-established in the literature as a risk factor for CI-AKI. The incidence of CI-AKI varies widely depending on the patient cohorts evaluated, definition criteria used, and preventive strategies adopted.\(^{31}\)

In conclusion, the current evidence indicates that rosuvastatin prevents the occurrence of CIN in patients after an episode of CI-AKI, especially in high-risk patients with DM or CKD.

The best approaches established so far to prevent CIN are to identify at-risk patients, provide adequate therapeutic doses, and minimize the amount of contrast administered. However, the actual mechanism by which statins may lower the risk of contrast nephropathy remains uncertain. Therefore, further research is needed to better understand their underlying mechanisms of action.

**Disclosure**

The authors report no conflicts of interest in this work.
References